This application for continuation of the Specialized Program of Research Excellence (SPORE) in Gastrointestinal Cancer at the Johns Hopkins Medical Institutions supports a highly interactive, multidisciplinary, and interinstitutional program. Eight research projects within four research programs, four cores, a career development and a research developmental program are proposed to further our translational research in colorectal and pancreatic cancer. Research Program 1: Applied Cancer Genetics (0012, Diagnosis and prognosis of human cancers through molecular genetic analyses, Dr. Kenneth Kinzler; 0002, New genetic clues in pancreatic cancer, Dr. Scott Kern). Program 2: Markers of Tumorigenesis (0013, Components of early and late pancreatic neoplasia, Dr. Scott Kern; 0008, Screening markers for high pancreatic cancer susceptibility, Dr. Michael Goggins). Program 3: Assessment of Familial Risk- (0014, Risk prediction in familial colorectal cancer, Dr. Giovanni Parmigiani; 0011, Markers for risk in familial pancreatic cancer, Dr. Ralph Hruban). Program 4: Therapeutic Directions (0015, Chemoprevention of human colorectal tumors, Dr. David Huso; 0016, Integration of chemotherapy with vaccination in metastatic pancreatic cancer, Dr. Elizabeth Jaffee). The cores support the research programs ( 9002, Human Tissue Research and Logistics, Dr. Elizabeth Montgomery; 9003, Familial Cancer Registries, Dr. Frank Giardiello; 9004, Statistics/Bioinformatics, Dr. Steven Goodman. The Career Development Program (Dr. Scott Kern) aids the emergence of new investigators and the Research Developmental Program (Dr. Bert Vogelstein) provides rapid funding of innovative directions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA062924-12
Application #
6910012
Study Section
Special Emphasis Panel (ZCA1-GRB-V (J1))
Program Officer
Agarwal, Rajeev K
Project Start
1993-09-30
Project End
2007-06-30
Budget Start
2005-08-31
Budget End
2006-06-30
Support Year
12
Fiscal Year
2005
Total Cost
$2,610,433
Indirect Cost
Name
Johns Hopkins University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Christmas, Brian J; Rafie, Christine I; Hopkins, Alexander C et al. (2018) Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs. Cancer Immunol Res 6:1561-1577
Blair, Alex B; Murphy, Adrian (2018) Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future. Curr Probl Cancer 42:49-58
Raman, Aadhithya; Lennon, Anne Marie (2018) Cyst Fluid Biomarkers - Diagnosis and Prediction of Malignancy for Cystic Lesions of the Pancreas. Visc Med 34:178-181
Noë, Michaël; Pea, Antonio; Luchini, Claudio et al. (2018) Whole-exome sequencing of duodenal neuroendocrine tumors in patients with neurofibromatosis type 1. Mod Pathol 31:1532-1538
Cohen, Joshua D; Li, Lu; Wang, Yuxuan et al. (2018) Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359:926-930
Shumar, Stephanie A; Kerr, Evan W; Geldenhuys, Werner J et al. (2018) Nudt19 is a renal CoA diphosphohydrolase with biochemical and regulatory properties that are distinct from the hepatic Nudt7 isoform. J Biol Chem 293:4134-4148
Li, Yuguo; Qiao, Yuan; Chen, Hanwei et al. (2018) Characterization of tumor vascular permeability using natural dextrans and CEST MRI. Magn Reson Med 79:1001-1009
Saung, May Tun; Muth, Stephen; Ding, Ding et al. (2018) Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer. J Immunother Cancer 6:118
Canto, Marcia Irene; Almario, Jose Alejandro; Schulick, Richard D et al. (2018) Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance. Gastroenterology 155:740-751.e2
Makohon-Moore, Alvin P; Matsukuma, Karen; Zhang, Ming et al. (2018) Precancerous neoplastic cells can move through the pancreatic ductal system. Nature 561:201-205

Showing the most recent 10 out of 883 publications